Jobs
View more job listings or post a job
Clovis Oncology Translational Medicine Operations Specialist
RAPT Therapeutics Director Drug Metabolism/Pharmacokinetics
UNIVERSITY OF CALIFORNIA, DAVIS TOXICOLOGY LAB MANAGER/SR ANALYTICAL CHEMIST (JOB POSTING #11305)
Genentech, Inc. Associate Director/ Director, Drug Discovery Outsourcing
PTC Therapeutics Director, Drug Metabolism and Pharmacokinetics (DMPK)
Frontier Medicines Principal Scientist Protein Sciences
Frontier Medicines Principal Scientist/Senior Scientist Biochemistry
Frontier Medicines Director/Associate Director Chemical Biology
Frontier Medicines Principal Scientist Chemical Biology
Frontier Medicines Scientist / Senior Scientist, Computational Chemistry
Frontier Medicines Scientist/Senior Scientist, in vivo pharmacology, Disease Biology
Frontier Medicines Senior R&D Scientific Systems and Software Engineer
Post a job

Symposium

[Free Online Symposium] No More Undruggables: Unconventional Approaches for Drug Discovery and Design - prodrugs, PROTACS, fragment-based design, directed evolution and beyond


Speakers: Michelle Arkin,PhD, Taylor Brew, PhD, John Knox, PhD, Daniel Erlanson, PhD, Mark Smith PhD,, Maureen Hillenmeyer, PhD, Ian Seiple, PhD, Chaitan Khosla, PhD
Organizers: Toni Kline, PhD
Date: 2020-10-29- 10/30/2020
Time: See About the Topic Section
Registration fee: (USD): Regular: $0
Location: Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2020-10-28  (it will close sooner if the seating cap is reached)

About the Topic

Proteins function in a physiological environment of access barriers, regulators, facilitators, and partners. In many therapeutic ecologies, the single drug-single target modal does not apply. To target these dynamics new modalities of both drug target and drug discovery are being explored. This Symposium will highlight some emerging ones.

Library screening, and modifications of known drugs have been engines of the discovery process for a century. Along with combinatorial chemistry and computer assisted drug discovery, these methods have brought thousands of molecules to the clinic. But a certain ”drug-like” sameness often appears across therapeutic groups. This may be for good reason (ADME, PK properties are optimized according to established conventions), but this sameness is at the expense of exploring truly novel chemical space. Happily, the discovery process is not static, and technologies are emerging to identify less obvious and less familiar-looking molecules. In the oncology and antibiotic spaces in particular, drugs arising from these methods might encounter less resistance. Much as we once naively talked about “junk DNA” and “undruggable” targets, we now have the insight and tools to understand the therapeutic potential inherent in complex biological systems.

Thursday, October 29, 2020 (all times US Pacific Time)

4:00 pm - 4:10 pm      Welcome & Introduction (Shichang Miao, Toni Kline)

4:10 pm - 4:35 pm      1. Stabilizing Protein-Protein Interactions: augmenting natural regulatory signals (Michelle Arkin, UCSF)

4:45 pm - 5:10 pm      2. Synthetic Lethality (Taylor Brew, Engine Biosciences)

5:20 pm – 5:45 pm     3. Allosteric inhibitors (John Knox, Revolution Medicines) 

5:55 pm - 6:10 pm      Break

6:10 pm - 6:35 pm      4. Fragment based drug discovery (Daniel Erlanson, Frontier Medicines)

6:45 pm - 7:00pm       Panel Discussion

Friday, October 30, 2020 (all times US Pacific Time)

9:00 am - 9:10 am       Introduction (Toni Kline)

9:10 am - 9:35 am       1. Discovery at the Academia/Biotech Borderline (Mark Smith, ChEM-H)

9:45 am - 10:10 am     2. AI meets Fermentation (Maureen Hillenmeyer, Hexagon Bio)

10:20 am - 10:30 am   Break

10:30 am -10:55 am    3. Access to Complex Natural Products (Ian Seiple, UCSF)

11:05 am -11:30 am    4. Directed Evolution (Chaitan Khosla, Stanford)

11:40 am - noon          Panel Discussion


2020-11-13, [Free Online Symposium] The Drug Discovery and Development Journey of Polivy™ (Polatuzumab Vedotin): An Antibody-Drug Conjugate for the Treatment of Diffuse Large B-cell Lymphoma
2021-07-29, Development of Inhalation Therapeutics (a joint symposium by AAPS-BADGE / PBSS / Genentech)
©Pharmaceutical & BioScience Society, International; Last Modified: 10/23/2020; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Eurofins Discovery Phenotypic Services Take a human-centered unbiased approach to drug discovery: Our Phenotypic Center of Excellence features BioMAP®, Biomarker, and OncoPanel™ Services
Eurofins Discovery Biomarker Services Cytokine Storm Assay for immunosafety profiles, STING Assay for in-depth evaluation of immune impacts; 360+ multiparameter flow cytometry capabilities
Eurofins Discovery On-Demand Take a coffee break with Discovery On-Demand! Mini webinars for remote learning avail 24/7 to accelerate your drug discovery program with confidence.
BioPharmEquip cGMP isolators, adherent-cell bioreactors, stability, CCIT + HGA, viable air sampler, -80C biorepository walk-ins, vH202
Alturas Analytics, Inc. Expert GLP & non-GLP LC-MS/MS, GC-MS/MS bioanalytical & PK/TK analysis services of small & large molecules in any matrix. Discovery through phase IV.
Hypha Discovery Limited Experts in drug metabolite synthesis & purification including CYP, AOX, FMO metabolites as well as O-, N-, acyl- glucuronides, glycosides & sulfates.
Submit a Text Ad